Medivation (MDVN) Target Lifted at Maxim Group
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
Tweet
Share
E-mailGet Alerts MDVN Hot Sheet
Price: $81.44 --0%
Rating Summary:
12 Buy, 17 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 17 | New: 31
Rating Summary:
12 Buy, 17 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 17 | New: 31
Join SI Premium – FREE
Maxim Group analyst Jason Kolbert reiterated a Buy rating on Medivation (NASDAQ: MDVN) and raised his price target from $92 to $112 as he extends his model to 2020.
Kolbert comments, " Last week, we reviewed our model and spent some time discussing Medivation’s recent guidance with management. As a result, we are extending our model out to 2020. We include a stream of milestone payments and adjust our R&D and G&A (higher). We conclude that 2014 is an “investment year,” during which the company will be building its infrastructure. This translates into a bolus sales force expansion and higher head counts, which impact both R&D and G&A. "
For an analyst ratings summary and ratings history on Medivation click here. For more ratings news on Medivation click here.
Shares of Medivation closed at $67.76 yesterday.
Kolbert comments, " Last week, we reviewed our model and spent some time discussing Medivation’s recent guidance with management. As a result, we are extending our model out to 2020. We include a stream of milestone payments and adjust our R&D and G&A (higher). We conclude that 2014 is an “investment year,” during which the company will be building its infrastructure. This translates into a bolus sales force expansion and higher head counts, which impact both R&D and G&A. "
For an analyst ratings summary and ratings history on Medivation click here. For more ratings news on Medivation click here.
Shares of Medivation closed at $67.76 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Abbott Labs (ABT) PT Lowered to $125 at BTIG
- KeyCorp (KEY) PT Raised to $27 at DA Davidson on Solid Quarter
- The Blackstone Group (BX) PT Lowered to $130 at BMO Capital
Create E-mail Alert Related Categories
Analyst Comments, Analyst PT ChangeRelated Entities
Maxim GroupSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
